Clinical trials: TACE
Carcinoma, Hepatocellular
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Patients will be enrolled based on presence of HCC and eligibility for TACE. They will be randomized to one of two arms for imaging navigation to the optimal catheter location for chemotherapy injection to treat the first…
- Trial name
- NCT00926536
- Testing
- C-arm CT + DSA as needed, DSA only
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Stanford University
Carrelizumab Plus Lenvatinib Combined With TACE, Borderline Resectable Hepatocellular Carcinoma
The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
The effectiveness and safety of carmelizumab/lenvatinib combined with TACE in patients with borderline resectable hepatocellular carcinoma remain unknown.
- Trial name
- NCT05042336
- Testing
- camrelizumab/lenvatinib combined with TACE
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Sichuan University
Hepatocellular Carcinoma
Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)
Liver transplantation (LT) represents the best treatment for patients with selected, early stage hepatocellular carcinoma (HCC).
- Trial name
- RADBRI (NCT03172559)
- Testing
- Stereotactic body radiotherapy
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma
Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma
The purpose of this real-world study is to evaluate the safety and efficacy of lipiodol-TACE with idarubicin for hepatocellular carcinoma.
- Trial name
- NCT05280444
- Testing
- Idarubicin Hydrochloride for Injection
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Zhongda Hospital
HCC
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06844357
- Testing
- tirapazamine, Transarterial Embolization (TAE), TACE
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Hepatocellular Carcinoma (HCC)
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
This is a single-arm, single-center, prospective trial designed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with ipalimab/tuvonralimab (QL1706) in the peri-operative setting for…
- Trial name
- TITAN-HCC (NCT07268131)
- Testing
- TACE+QL1706
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Liver Cancer
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
- Trial name
- NCT07587034
- Testing
- HTAC, HAC, TAC
- Volunteers
- 315 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Liver Cancer
Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC
BACKGROUND: Hepatocellular carcinoma is the fifth most frequent cancer in the world, with a diagnosis of more than 500,000 new cases per year.
- Trial name
- NCT04653701
- Testing
- Chemoembolization with preloaded microparticles 100 micron and reflux control microcatheter
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juan José Ciampi Dopazo
Hepatocellular Carcinoma
A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma
The propose of this study is evaluate the safety and efficacy of MG4101 (allogeneic Natural killer cells) in patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE).
- Trial name
- NCT02854839
- Testing
- MG4101
- Where
- 6 sites in South Korea
- Volunteers
- 78 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma (HCC)
TACE for HCC by TANDEM and Idarubicin
DcBeads and lipiodol-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using doxorubicin result in about 50% objective response rate at 6 months (Precision V study, Lammer et al.
- Trial name
- TANDEM-IDA (NCT03349957)
- Testing
- Transarterial chemoembolization using TANDEM and idarubicin
- Where
- France
- Volunteers
- 98 people
- Sponsor
- University Hospital, Montpellier
HCC
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma
Although the combination of transarterial chemoembolization (TACE) with PD-1 inhibitor plus lenvatinib has become a new standard, the therapeutic efficacy for unresectable hepatocellular carcinoma (uHCC) still requires…
- Trial name
- NCT07340502
- Testing
- TACE, HAIC, PD-1inhibitors
- Volunteers
- 364 people
- Sponsor
- Tongji Hospital
Potentially Resection, Hepatocellular Carcinoma
TACE-HAIC vs. HAIC for Potentially Resectable HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- NCT03591705
- Testing
- TACE-HAIC, HAIC
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Lenvatinib
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
single-center clinical trial studies have verified the safety and effectiveness of transcatheter arterial chemoembolization (TACE) combined with lenvatinib in preventing postoperative recurrence of microvascular invasion (MVI)…
- Trial name
- NCT04911959
- Testing
- Lenvatinib, TACE
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of…
- Trial name
- NCT00522405
- Testing
- TACE
- Where
- India
- Sponsor
- All India Institute of Medical Sciences
Hepatocellular Carcinoma
Study in Asia of the Combination of TACE With Sorafenib in HCC Patients
TACE possibly plays a significant role in contributing to a subgroup of surviving residual tumor tissue which is characterized by more aggressive biology.
- Trial name
- START (NCT00990860)
- Testing
- doxorubicin, TACE (Transcatheter arterial chemoembolization)
- Where
- 8 sites in Taiwan
- Volunteers
- 36 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma
The aim of the study was to evaluate the safety and efficacy of using the new formulation (Lipiodol-cisplatin suspension) for TACE in the treatment of HCC as compared to the conventional formulation (Lipiodol-cisplatin emulsion).
- Trial name
- NCT03268499
- Testing
- Lipiodol-based transarterial chemoembolization
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
- Trial name
- NCT05842317
- Testing
- Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Cancer
An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)
This is a prospective, open-labelled study to evaluate the efficacy and safety of sequetial transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of initial unresectable colorectal cancer.
- Trial name
- NCT05340231
- Testing
- TACE protocol, Neoadjuvant Chemotherapy
- Volunteers
- 100 people
- Sponsor
- Gang Wu
Hepatocellular Carcinoma (HCC)
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of a combination therapy involving TACE, sintilimab, bevacizumab, and ipilimumab N01 for the treatment of advanced hepatocellular…
- Trial name
- NCT07422753
- Testing
- CTLA-4 Antibody(ipilimumab N01)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance Sorafenib will be taken after the completion of radiotherapy.
- Trial name
- NCT00999843
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University